SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., a privately-held company with a first-in-class, transcatheter-based structural heart device to treat heart failure, today announced that the U.S.
Treatment IDE Will Provide Opportunity to Treat Additional Patients in the US SAN RAMON, Calif., Jan. 24, 2023 /PRNewswire/ -- BioVentrix ®, Inc., a privately held medical device company focused on ...
SAN RAMON, Calif., and XIAMEN, China, March 13, 2017 /PRNewswire/ -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced ...
SAN RAMON, Calif.--(BUSINESS WIRE)--BioVentrix, Inc., developer of the first less invasive system for left ventricular remodeling, today announced online publication of positive one-year results from ...
The Revivent TC™TransCatheter Ventricular Enhancement System enables the treatment and management of patients who suffered a myocardial infarction resulting in left ventricular dysfunction SAN RAMON, ...
SAN RAMON, Calif. and MAINZ, Germany, April 17, 2017 /PRNewswire/ -- BioVentrix, Inc. a pioneer of technologies and procedures for less invasive treatment of heart failure (HF), today announced the ...
The BioVentrix Revivent TC System is designed to support a minimally invasive procedure to treat a dilated left ventricle of patients with ischemic heart failure with reduced ejection fraction (HFrEF) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results